Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,401–7,500 of 15,747
Immune response to mRNA ‐based COVID ‐19 booster vaccination in people living with HIV
Malin, J. J., Suárez, I., Biehl, L. M., Schommers, P., Knops, E., Cristanziano, V. D., Heger, E., Pflieger, E., Wyen, C., Bettin, D., et al. (2023) · HIV Medicine · doi:10.1111/hiv.13481 · Cited by 9
“While messenger RNA (mRNA)-based vaccines have been shown to be extremely effective in large randomized controlled trials in healthy individuals [3, 4], only smaller observational studies have addressed mRNA vaccine immunogenicity in people living with HIV, and few have assessed factors of influence.”
BackgroundBNT162b2 Covid-19 Vaccine in Adolescents
Lin, C.-H. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2113394 · Cited by 9
Self-citationLiu, S., Zhang, L., Fu, W., Liang, Z., Yu, Y., Li, T., Tong, J., Liu, F., Nie, J., Lu, Q., et al. (2024) · MedComm · doi:10.1002/mco2.615 · Cited by 9
Dynamics of a mathematical model of virus spreading incorporating the effect of a vaccine
Gökçe, A., Gürbüz, B., & Rendall, A. D. (2024) · Nonlinear Analysis Real World Applications · doi:10.1016/j.nonrwa.2024.104097 · Cited by 9
The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines
Lu, H., Xiao, J., Song, J., Song, Y., Li, H., Ren, H., Li, J., Cong, R., Li, H., Fang, Y., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70201 · Cited by 10
“Moderna and BioNTech are at the forefront of the mRNA field and have developed the mRNA ‐ BNT162b2 and mRNA ‐ 1273 vaccines, respectively, for severe acute respiratory syndrome coronavirus 2 (SARS ‐ CoV ‐ 2) [48, 49].”
Mimouni, H., Bahouh, C., Amaqdouf, S., Laaribi, I., Baddi, M., Berichi, S., Bkiyar, H., Ismaili, N., Ouafi, N. E., & Housni, B. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.103210 · Cited by 12
“The efficacy of mRNA vaccine in preventing COVID-19 infection in participants aged 16 – 55 years is 94 – 95%, and is 100% in children aged 12 – 15 years [7].”
Anti-S and Anti-N Antibody Responses of COVID-19 Vaccine Recipients
Al-Shudifat, A.-E., Al‐Tamimi, M., Dawoud, R., Alkhateeb, M., Mryyian, A., Al-Ahmad, A., Abbas, M. M., & Qaqish, A. (2023) · Vaccines · doi:10.3390/vaccines11091398 · Cited by 11
“Regarding symptom severity and need for hospitalization, the Pfizer vaccine has shown a 95% efficacy rate in preventing future infections with SARS-CoV-2 [13].”
InfluentialPadhiar, N. H., Liu, J., Wang, X., Wang, X., Bodnar, B. H., Khan, S., Wang, P., Khan, A. I., Luo, J. J., Hu, W., et al. (2022) · Vaccines · doi:10.3390/vaccines10060858 · Cited by 10
SARS-CoV-2 vaccines in children and adolescents: Can immunization prevent hospitalization?
Liang, K., Hung, K.-F., Wang, M., Chang, T.-J., Cheng, Y., Chiang, S., Chen, M., Liao, Y.-T., Chiou, S., & Yang, D. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000774 · Cited by 9
Reeves, D. B., Bracis, C., Swan, D. A., Burns, E., Moore, M., Dimitrov, D., & Schiffer, J. T. (2021) · Med · doi:10.1016/j.medj.2021.04.012 · Cited by 7
“COVID-19 vaccine efficacy was originally measured as reductions in symptomatic disease.(3,4) Therefore, we assume vaccines can achieve this efficacy by three mechanisms: infection is completely blocked (susceptibility, VESUSC), symptoms are blocked despite infection (VESYMP), and/or secondary transmission is blocked d…”
BackgroundSARS-CoV-2 B 1.1.7 Variant Outbreak in a Fully Vaccinated Nursing Home—Madrid, June 2021
Mateos‐Nozal, J., Montemayor, J. C. G., Torres, S. L., et al. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.08.032 · Cited by 9
Tachita, T., Takahata, T., Yamashita, S., Ebina, T., Kamata, K., Yamagata, K., Tamai, Y., & Sakuraba, H. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03607-w · Cited by 12
Reactive arthritis after COVID-19 vaccination: 17 cases
Golstein, M. A., Fagnart, O., & Steinfeld, S. D. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead169 · Cited by 9
Muñoz-Moreno, R., Allaj, V., Gadee, E., Button, J. M., Diaz, F., Maddur, M. S., Chen, W., Hu, C. H., Martinez, L. T., Giannakou, A., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01093-1 · Cited by 11
Lee, K. J., Choi, S. Y., Lee, Y. M., & Kim, H. W. (2022) · Vaccines · doi:10.3390/vaccines10081265 · Cited by 10
“IBD patients were excluded from the BNT162b2 clinical trials [2]; therefore, real-world data and some prospective studies have recently been reported in this population [16–19].”
BackgroundMethodMoghadas, S., Fitzpatrick, M., Shoukat, A., et al. (2021) · medRxiv · doi:10.1101/2021.01.06.21249349 · Cited by 26
Lin, F. J., Doss, A. M. A., Davis-Adams, H. G., Adams, L. J., Hanson, C. H., VanBlargan, L. A., Liang, C.-Y., Chen, R. E., Monroy, J. M., Wedner, H. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033770 · Cited by 10
Sahn, B. A., Lu, Y., Hui‐Yuen, J. S., Fishbein, J. S., Gottlieb, B. S., Eberhard, B. A., & Walters, H. M. (2022) · Acta Paediatrica · doi:10.1111/apa.16652 · Cited by 9
Salsone, M., Signorelli, C., Oldani, A., Patone, M., Alberti, V. F., Castronovo, V., Mazzitelli, S., Minerva, M., & Ferini‐Strambi, L. (2023) · Vaccines · doi:10.3390/vaccines11101621 · Cited by 11
Cauchi, M., Ball, H. A., Ben‐Shlomo, Y., & Robertson, N. P. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10747-8 · Cited by 11
Velardo, F., Watson, V., Arwidson, P., Alla, F., Luchini, S., Schwarzinger, M., & CoVaMax Study Group (2021) · Vaccines · doi:10.3390/vaccines9111364 · Cited by 8
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants
Chatterjee, B., & Thakur, S. S. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.1997601 · Cited by 13
“individuals that included 21,720 people receiving BNT162b2 injection while 21,728 people receiving placebo [56].”
BackgroundImunização contra covid-19 e mortalidade em pacientes hospitalizados: coorte retrospectiva
Fernández, M., de Figueiredo, A. M., Massuda, A., Neto, A. H. D. M., & de Carvalho, M. W. A. (2024) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2024058005476 · Cited by 13
“The vaccines used in Brazil are highly effective in preventing moderate and severe cases, which can be observed in clinical trials 12–14 and effectiveness studies in other countries 15–17 .”
BackgroundPark, J.-S., Minn, D., Hong, S., Jeong, S., Kim, S., Lee, C. H., & Kim, B. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e180 · Cited by 9
“106 6 (100) Day 7, from 2nd dose 55 (100) 25 (100) 6 (100) Day 50, from 2nd dose 55 (100) 25 (100) 6 (100) Proportion of positive result of SARS-CoV-2 neutralizing antibody activity measured by cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit Day 0, from 1st dose 1 (2) 0 1.”
MethodVirtual conferences: results of an international survey on radiologist preferences and perspectives
D’Anna, G., Ugga, L., Cuocolo, R., et al. (2022) · European Radiology · doi:10.1007/s00330-022-08903-3 · Cited by 9
Maltseva, M., Galipeau, Y., McCluskie, P. S., Castonguay, N., Cooper, C., & Langlois, M. (2025) · Vaccines · doi:10.3390/vaccines13040351 · Cited by 9
Farhadian, N., Sharifi, S., Taghadosi, M., Farhadian, M., & Vaziri, S. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2451 · Cited by 9
“Considering that a weak serological response to the vaccine among PLWH has been observed against other common vaccines such as influenza,(25) pneumococcal,(26) hepatitis A,(27,28) and hepatitis B,(29,30) PLWH may also have a suboptimal response to the COVID‐19 vaccination.(15,31,32) There are several studies and a met…”
BackgroundInfluentialCorrelation Between Malpractice Litigation and Legislation Reform in Taiwan Over a 30-Year Period
Hsieh, M.-T., Lu, L.-H., Lin, C.-W., & Chen, Y. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s312640 · Cited by 9
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients
Stanghellini, M. T. L., Cosimo, S. D., Costantini, M., Monti, S. M., Mantegazza, R., Mantovani, A., Salvarani, C., Zinzani, P. L., Inglese, M., Ciceri, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.855723 · Cited by 9
“No grade 4 adverse events were reported Cancer (19, 21, 38–42, 44, 45) 2,387 739 healthy subjects BNT162b2 mRNA-1273 ChAdOx1 Solicited and unsolicited AE collection through faceto-face or telephone consultations (19).”
BackgroundMethodInfluentialGlobal Trends in mHealth and Medical Education Research: Bibliometrics and Knowledge Graph Analysis
He, Y., Xie, Z., Li, J., Meng, Z., Xue, D., & Hao, C. (2024) · JMIR Medical Education · doi:10.2196/52461 · Cited by 9
“Additionally, there were peaks in the LCS detected in 2008 (7), 2013 (14), 2014 (14), and 2016 (15), indicating that studies in these years had large contributions to the research published in this field in the subsequent years.”
BackgroundAutoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations
Yu, C., Wang, W., Zhang, Q., & Jin, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1510770 · Cited by 9
COVID-19 pandemic and the answer of science: a year in review
OLIVEIRA, E. A., Oliveira, M. C. L., Martelli, D. R. B., Colosimo, E. A., Silva, L. R., Lanza, K., Júnior, H. M., & Silva, A. C. S. E. (2021) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202120210543 · Cited by 13
Orbital inflammatory disease following mRNA SARS‐CoV‐2 vaccine
Grunenwald, S., Lethellier, G., Imbert, P., et al. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5926 · Cited by 9
Chemical strategies for brain delivery of genomic therapy
Li, H., Yu, C., Markovic, T., Nestler, E. J., & Dong, Y. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00770-y · Cited by 17
Bazin, R., Rochette, S., Perreault, J., Fournier, M., Grégoire, Y., Boivin, A., Lewin, A., Germain, M., & Renaud, C. (2023) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2023.2195938 · Cited by 12
The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo
Brook, B., Fatou, B., Checkervarty, A., Barman, S., Sweitzer, C., Bosco, A.-N., Sherman, A., Baden, L., Morrocchi, E., Sánchez‐Schmitz, G., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111055 · Cited by 16
Gustafsson, O., Krishna, S., Borate, S., Ghaeidamini, M., Liang, X., Saher, O., Cuellar, R., Birdsong, B. K., Roudi, S., Estupiñan, H. Y., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114038 · Cited by 11
Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., & Björkman, P. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.26.521940 · Cited by 10
Yu, S., Choi, M., Cheong, C., Ryoo, S., Huh, K., Yoon, Y. K., Choi, J., & Kim, S. B. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.07.009 · Cited by 11
Fair and effective vaccine allocation during a pandemic
Erdoğan, G., Yücel, E., Kiavash, P., & Salman, F. S. (2024) · Socio-Economic Planning Sciences · doi:10.1016/j.seps.2024.101895 · Cited by 9
Assessing Public Health and Social Measures Against COVID-19 in Japan From March to June 2021
Hayashi, K., Kayano, T., Anzai, A., Fujimoto, M., Linton, N. M., Sasanami, M., Suzuki, A., Kobayashi, T., Otani, K., Yamauchi, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.937732 · Cited by 15
“During the study period, random sampling of PCR-positive patients in Japan was conducted to screen for the N501Y point mutation that was commonly seen in the Alpha variant (B.1.1.7) using real time RT-PCR, so as to estimate the percentage of infections with this variant (49).”
BackgroundInfluentialChen, G., Qiu, Y., Wu, K., Wu, Y., Wang, Y., Zou, Y.-Y., Peng, C., Zhao, J., Su, C., Ma, J.-H., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2285089 · Cited by 9
“6,7,17 Again, this phenomenon should be further studied in a larger sample in order to test the robustness.”
BackgroundAssessing acute kidney injury risk after COVID vaccination and infection in a large cohort study
Pan, Y., Han, Y., Zhou, C., Zheng, J., Zhao, L., Ye, X., He, Y. O., Koraishy, F. M., & Chute, C. G. (2024) · npj Vaccines · doi:10.1038/s41541-024-00964-3 · Cited by 10
Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy
Xu, F., Ni, Q., Gong, N., Xia, B., Zhang, J., Guo, W., Hu, Z., Li, J., & Liang, X. (2024) · Advanced Materials · doi:10.1002/adma.202407525 · Cited by 13
den Hartog, Y., Malahe, S. R. K., Rietdijk, W. J. R., Dieterich, M., Gommers, L., Geers, D., Bogers, S., van Baarle, D., Diavatopoulos, D. A., Messchendorp, A. L., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00664-4 · Cited by 8
Evaluation of the Moderna, Pfizer/Biotech, Astrazeneca/Oxford and Sputnik V Vaccines for Covid-19
Soto, J. A. D. (2021) · Advance Research Journal of medical clinical and science · doi:10.15520/arjmcs.v7i01.246 · Cited by 15
Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants
Tubjaroen, C., Prachuapthunyachart, S., Potjalongsilp, N., Sodsai, P., Hirankarn, N., Jaru-Ampornpan, P., & Chongsrisawat, V. (2022) · Vaccines · doi:10.3390/vaccines10111867 · Cited by 9
“When stratified by age, there were no significant differences in vaccine efficacy, which was 95% in the young obese adults aged 16–24 years [36].”
Background(2021) · doi:10.1101/2021.07.09.21260272 · Cited by 9
“21,23 Additionally, we explored a range of vaccine profiles (see Figure 2, E).”
Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond
Ji, R., Chen, Q., & Zhang, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102459 · Cited by 19
“100 Owing to the liver’s unique vascular structure and its natural role in nanoparticle clearance, LNPs efficiently target hepatocytes, enabling co-delivery of CRISPR mRNA and sgRNA for effective genome editing and treatment of liver-associated genetic disorders, as demonstrated in clinical studies.”
Role of imaging in rare COVID-19 vaccine multiorgan complications
Cau, R., Mantini, C., Monti, L., Mannelli, L., Dedda, E. D., Mahammedi, A., Nicola, R., Roubil, J. G., Suri, J. S., Cerrone, G., et al. (2022) · Insights into Imaging · doi:10.1186/s13244-022-01176-w · Cited by 10
“The most commonly described side effects after COVID-19 vaccination are pain at the injection site, fever, muscle pain, fatigue, and headache [4].”
BackgroundYi, H., Wang, Q., Deng, J., Li, H., Zhang, Y., Chen, Z., Ji, T., Liu, W., Zheng, X., Ma, Q., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.06.006 · Cited by 13
“HAdV26-based vaccine expressing HIV-1 envelope protein (Env) can elicit broad and diverse antigen-specific humoral and cellular immune responses in humans (Baden et al., 2013; Barouch et al., 2013; Logunov et al., 2020a; Sadoff et al., 2021b; Vergnes, 2021).”
BackgroundParanthaman, K., Subbarao, S., Andrews, N. J., Kirsebom, F. C. M., Gower, C., Bernal, J. L., Ramsay, M. E., & Copas, A. J. (2022) · Age and Ageing · doi:10.1093/ageing/afac115 · Cited by 11
“To date, multiple vaccines have been developed and approved for use [2, 3].”
BackgroundPreventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes
Lyu, X., Imai, S., Yamano, T., & Hanayama, R. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03400-0 · Cited by 8
“In addition, FDA-approved COVID-19 vaccines produced by Pfizer-BioNTech and Moderna have been applied to individuals worldwide to produce neutralizing antibodies to prevent SARS-CoV-2 infection [6, 7].”
BackgroundNew‐onset vitiligo after COVID ‐19 mRNA vaccination: A causal association?
Nicolaidou, E., Vavouli, C., Koumprentziotis, I., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18513 · Cited by 9
Horwitz, R. I., & Cullen, M. R. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000533449 · Cited by 9
Liu, Y., Sánchez‐Ovando, S., Carolan, L. A., Dowson, L., Khvorov, A., Hadiprodjo, A. J., Tseng, Y. Y., Delahunty, C., Khatami, A., Macnish, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.034 · Cited by 13
Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus
Mamais, I., Malatras, A., Papagregoriou, G., Giallourou, N., Kakouri, A. C., Karayiannis, P., Koliou, M., Christaki, E., Nikolopoulos, G. K., & Deltas, C. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245882 · Cited by 8
High acceptance rate of COVID-19 vaccination in liver transplant recipients
Giannini, E. G., & Marenco, S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.009 · Cited by 9
SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease
Elkharsawi, A. R., von Arnim, U., Schmelz, R., Sander, C., Stallmach, A., Teich, N., Walldorf, J., & Reuken, P. A. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1710-3861 · Cited by 9
“Rates of local and systemic adverse reactions were comparable to those seen in clinical trials[10].”
(2021) · doi:10.21203/rs.3.rs-580444/v1 · Cited by 425
Amano, M., Otsu, S., Maeda, K., Uemura, Y., Shimizu, Y., Omata, K., Matsuoka, M., Shimada, S., & Mitsuya, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-17071-9 · Cited by 10
Parthymou, A., Habeos, E. E., Habeos, G. I., Deligakis, A., Livieratos, E., Marangos, M., & Chartoumpekis, D. (2021) · medRxiv · doi:10.1101/2021.09.01.21262913 · Cited by 6
Temtanakitpaisan, Y., Saengnipanthkul, S., Sarakosol, N., Maskasame, S., Mongkon, S., Buranrat, B., Thammawat, S., Patamatamkul, S., & Nernsai, P. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100242 · Cited by 9
“The mRNA vaccines provided high efficacy (95 % from the BNT162b2 mRNA vaccine [14] and 94.”
Lieber, C. M., Cox, R. M., Sourimant, J., Wolf, J. D., Juergens, K. B., Phung, Q., Saindane, M., Natchus, M. G., Painter, G. R., Sakamoto, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.04.479171 · Cited by 9
Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies
Forde, J. E., & Ciupe, S. M. (2021) · Viruses · doi:10.3390/v13122546 · Cited by 12
Inada, M., Ishikane, M., Terada, M., Matsunaga, A., Maeda, K., Tsuchiya, K., Miura, K., Sairenji, Y., Kinoshita, N., Ujiie, M., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.04.017 · Cited by 10
“First, SARS-CoV-2 mRNA vaccination successfully induced neutralizing antibody and showed efficacy for protection [18,19].”
Nakai, M., Yokoyama, D., Sato, T., Sato, R., Kojima, C., & Shimosawa, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16547 · Cited by 10
“In this context, the BioNTech/Pfizer BNT162b2 messenger RNA (mRNA) vaccine, the first COVID-19 vaccine to receive approval, shows efficiency and is being widely used [4].”
SARS-CoV-2 mRNA vaccination–induced immunological memory in human nonlymphoid and lymphoid tissues
Proß, V., Sattler, A., Lukassen, S., Toth, L., Thole, L. M. L., Siegle, J., Stahl, C., He, A., Damm, G., Seehofer, D., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171797 · Cited by 11
“Vaccination against SARS-CoV-2 has been proven in large cohort studies (1, 2) to be a powerful strategy to protect from severe coro-navirus disease 2019 ( COVID-19 COVID-19).”
Alturaiki, W., Mubarak, A., Jurayyan, A. A., & Hemida, M. G. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1935172 · Cited by 11
“This vaccine is showing 95% protection against the development of severe COVID-19 cases.(77)”
BackgroundMethodCOVID-19 vaccination: an attempt to control the pandemic
Armin, S., Wakil, A., Tarbox, J. A., & IWUJI, K. C. (2021) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v9i37.801 · Cited by 9
Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2Preprint
Dangi, T., Sanchez, S., Park, M.-C., Class, J., Richner, M., Richner, J. M., & Penaloza‐MacMaster, P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.09.483635 · Cited by 8
Vahed, H., Prakash, S., Quadiri, A., Ibraim, I. C., Omorogieva, E., Patel, S., Tadros, J., Liao, E. J., Lau, L., Chentoufi, A. A., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2527438 · Cited by 10
Terpos, E., Liontos, M., Fiste, O., Zagouri, F., Briasoulis, Α., Sklirou, A. D., Markellos, C., Skafida, E., Papatheodoridi, A. M., Andrikopoulou, Α., et al. (2022) · Cancers · doi:10.3390/cancers14112796 · Cited by 9
“Up to March 2022, five vaccines had shown clinical efficacy and were approved by the European Medical Agency (EMA), namely BNT162b2, developed by Pfizer BioNTech [6]; NVX-CoV2373, developed by Novavax [7]; mRNA-1273, developed by Moderna; NIAID [8], AZD1222, developed by the University of Oxford and AstraZeneca [9]; a…”
Olszewska, B., Zaryczańska, A., Nowicki, R. J., & Sokołowska‐Wojdyło, M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1325478 · Cited by 12
Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation
Talemi, M. N., Farani, M. R., Eskandani, N. A., Mirzaee, D., Alipourfard, I., & Huh, Y. S. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102774 · Cited by 30
“The COVID-19 mRNA vaccines then demonstrated global scalability of LNP-mRNA formulations and the robustness of their performance across diverse populations, moving the field from proof-of-concept to mass deployment [18,28].”
Zheng, B., Campbell, J., Carr, E. J., Tazare, J., Nab, L., Mahalingasivam, V., Mehrkar, A., Santhakumaran, S., Steenkamp, R. D., Loud, F. C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad184 · Cited by 8
Lionis, C. D., Karakasiliοtis, I., Petelos, E., Linardakis, M., Diamantakis, A., Symvoulakis, E. K., Panopoulou, M. I., Kampa, M., Pirintsos, S., Sourvinos, G., et al. (2021) · medRxiv · doi:10.1101/2021.01.11.20248947 · Cited by 12
Takemoto, Y., Tanimine, N., Yoshinaka, H., Tanaka, Y., Takafuta, T., Sugiyama, A., Tanaka, J., & Ohdan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1217206 · Cited by 10
Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Wiesch, J. S. Z., Bokemeyer, C., Sinn, M., Weisel, K. C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235499 · Cited by 9
Meier, N. F., Perner, A., Plovsing, R. R., Christensen, S., Poulsen, L. M., Brøchner, A. C., Rasmussen, B. S., Helleberg, M., Jensen, J. S., Andersen, L. P., et al. (2023) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.14290 · Cited by 9
“Omicron 8 (4) 92 (30) Delta 154 (82) 38 (13) Unknown 170 (14) 197 (57) Comorbidities, N (%) Hypertension 153 (46) 135 (41) Ischemic heart disease 48 (15) 47 (14) Heart failure 29 (9) 32 (10) Chronic pulmonary disease 62 (19) 91 (28) Chronic kidney disease 33 (10) 34 (10) Liver cirrhosis 5 (2) 11 (3) Diabetes 71 (21) 6…”
Khatrawi, E. M., & Sayed, A. A. (2022) · Cureus · doi:10.7759/cureus.33042 · Cited by 9
“This variant likely requires a booster dose of the vaccine to be more effective in tackling the infection and reduce the severity of the disease, and thus the deaths [14-18].”
BackgroundWaning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar
(2021) · doi:10.1101/2021.12.16.21267902 · Cited by 831
Cari, L., Alhosseini, M. N., Bergamo, A., Pacor, S., Pierno, S., Sava, G., & Nocentini, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.967926 · Cited by 9
de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Corzo, C. A. C., Hueda-Zavaleta, M., Siles, D. A., & Benites-Zapata, V. A. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050066 · Cited by 11
New ionizable lipids for non-viral mRNA delivery with secondary amine cyclic ether head groups
Dane, E. L., Pote, A. R., Hemmerling, M., Czechtizky, W., Zhou, L., & Bak, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00115c · Cited by 11
Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic
Mukherji, R., & Marshall, J. L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00888-3 · Cited by 9
Pan, Y., Han, Y., Zhou, C., Zhao, L., Zheng, J., Ye, X., He, Y. O., & Chute, C. G. (2025) · Nature Communications · doi:10.1038/s41467-025-61613-4 · Cited by 14
The mRNA-Based Innovative Strategy: Progress and Challenges
Zhou, H., Wei, D., Chen, Z., Chen, H., Dong, C., Cai, W., Wang, J., Liu, X., Li, Y., Yang, Y., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-025-01906-x · Cited by 24
“The current applications have spanned epidemic vaccine [19, 20], cancer vaccine [28–30], protein replacement therapy [24], cytokine therapy [31, 32], cell therapy [33, 34] and gene editing [21, 35], serving as crucial complements for traditional medical therapies.”
(2021) · doi:10.1101/2021.08.18.21262214 · Cited by 9
“Even if live or synthetic viruses are used to react with samples to detect the killing ability of NAbs against viruses in samples, the clinical efficacy evaluation of vaccines published now is all using this method [5, 8].”
MethodOrsi, A., Domnich, A., Pace, V. D., Ricucci, V., Caligiuri, P., Bottiglieri, L., Vagge, R., Cavalleri, M., Orlandini, F., Bruzzone, B. M., et al. (2021) · Vaccines · doi:10.3390/vaccines9060591 · Cited by 14
“The available phase III randomized controlled trial [18] suggests a high efficacy (>94%) of the BNT162b2 vaccine in the elderly.”
BackgroundForgacs, D., Moraes, V. S., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. (2022) · bioRxiv · doi:10.1101/2022.03.16.484099 · Cited by 8
Generalidades, aspectos clínicos y de prevención sobre COVID-19: México y Latinoamérica
Fernández, J. A. M., & Wong‐Chew, R. M. (2021) · Universitas Médica · doi:10.11144/javeriana.umed62-3.gacp · Cited by 25
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.